Page last updated: 2024-12-06

enadoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

enadoline: kappa-opioid receptor agonist; RN given refers to cpd without isomeric designation; PD 129290 (CAM 570; CI 977) is the S,S(-)-enantiomer; PD 129289 (CAM 569) is the corresponding R,R(+)-enantiomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60768
CHEMBL ID318859
SCHEMBL ID220053
MeSH IDM0184021

Synonyms (36)

Synonym
2-(1-benzofuran-4-yl)-n-methyl-n-[(5r,7s,8s)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
ci977
gtpl1646
ci 977
enadoline
CHEMBL318859 ,
1-{(5r,7s,8s)-8-[(2-benzofuran-4-yl-acetyl)-methyl-amino]-1-oxa-spiro[4.5]dec-7-yl}-pyrrolidinium
bdbm50290967
2-benzofuran-4-yl-n-methyl-n-((5r,7s,8s)-7-pyrrolidin-1-yl-1-oxa-spiro[4.5]dec-8-yl)-acetamide
NCGC00248028-01
4-benzofuranacetamide, n-methyl-n-((5r,7s,8s)-7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-
NCGC00254402-01
tox21_300426
dtxsid4047258 ,
cas-124378-77-4
dtxcid2027258
unii-kjl283326c
124378-77-4
kjl283326c ,
4-benzofuranacetamide, n-methyl-n-(7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-, (5r-(5alpha,7alpha,8beta))-
hsdb 7677
enadoline [inn]
enadoline [hsdb]
n-methyl-n-((5r,7s,8s)-7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-4-benzofuranacetamide
4-benzofuranacetamide, n-methyl-n-(7-(1-pyrrolidinyl)-1-oxaspiro(4.5)dec-8-yl)-, (5r-(5.alpha.,7.alpha.,8.beta.))-
[3h]ci-977
gtpl3475
[3h]-ci977
[3h]enadoline
[3h]ci977
[3h]-enadoline
SCHEMBL220053
2-(benzofuran-4-yl)-n-methyl-n-((5r,7s,8s)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-yl)acetamide
Q5375164
2-(benzo[b]furan-4-yl)-n-methyl-n-((5r,7s,8s)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-yl)acetamide
A910120

Research Excerpts

Overview

Enadoline is a highly selective and potent kappa-opioid receptor agonist. The neonates were eight times more sensitive than the adults.

ExcerptReferenceRelevance
"Enadoline was found to be a potent antinociceptive agent in the formalin test; the neonates were eight times more sensitive than the adults."( Analysis of the antinociceptive actions of the kappa-opioid agonist enadoline (CI-977) in neonatal and adult rats: comparison to kappa-opioid receptor mRNA ontogeny.
Abood, ME; McLaughlin, CR; Tao, Q, 1995
)
1.25
"Enadoline is a highly selective and potent kappa-opioid receptor agonist. "( Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain.
Carnell, AJ; Field, MJ; Gonzalez, MI; Hughes, J; McCleary, S; Oles, RJ; Singh, L; Smith, R, 1999
)
3.19

Toxicity

ExcerptReferenceRelevance
" The most frequently reported adverse events after CI-977 administration were dizziness, fatigue, paresthesia, headache, vasodilatation (facial flushing), emotional lability, high feeling, and abnormal thinking."( Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans.
Dawkins, R; Rajagopalan, R; Reece, PA; Rose, S; Sedman, AJ; Wright, DS, 1994
)
0.29
" Taken together, these results demonstrate that MPClE is a novel, potent, orally active and safe analgesic drug that targets κ-opioid receptors."( A novel, potent, oral active and safe antinociceptive pyrazole targeting kappa opioid receptors.
Athayde, ML; Boligon, AA; Bonacorso, HG; Calixto, JB; Ferreira, J; Machado, P; Martins, MA; Oliveira, SM; Rosa, F; Rossato, MF; Rubin, MA; Silva, CR; Tonello, R; Trevisan, G; Walker, CI; Zanatta, N, 2013
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
" This 8-week inpatient study examined the ability of enadoline, a selective and high-efficacy kappa-agonist, and butorphanol, a mixed agonist with intermediate efficacy at both mu- and kappa-receptors, to reduce the direct pharmacodynamic effects and self-administration of intravenous cocaine in humans (n = 8)."( Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans.
Bigelow, GE; Geter-Douglas, B; Strain, EC; Walsh, SL, 2001
)
2

Compound-Compound Interactions

ExcerptReferenceRelevance
"Effects of the kappa opioid agonists, spiradoline (U62,066), enadoline (CI-977) and U69,593, were examined alone and in combination with the opioid antagonists quadazocine and beta-funaltrexamine in squirrel monkeys that responded under a schedule of shock titration."( Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys.
Dykstra, LA; Pitts, RC, 1994
)
0.75
" When given in combination with cocaine, EKC produced effects that were sub-additive, suggesting that the kappa agonists may be used safely as cocaine abuse treatments."( Effects of kappa opioid agonists alone and in combination with cocaine on heart rate and blood pressure in conscious squirrel monkeys.
Bergman, J; Gilman, JP; Goldberg, SR; Graczyk, Z; Mello, NK; Negus, SS; Schindler, CW, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves were generated for both delta 9-THC (i."( Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.
Martin, BR; Smith, PB; Welch, SP, 1994
)
0.29
" These data suggest that these kappa-agonists may be safely administered in the presence of cocaine but do not produce significant attenuation of cocaine's direct effects or self-administration under these acute dosing conditions."( Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans.
Bigelow, GE; Geter-Douglas, B; Strain, EC; Walsh, SL, 2001
)
1.75
"0 mg/kg) attenuated the priming effects of cocaine, shifting the cocaine dose-response function rightward and downward."( Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms.
Platt, DM; Rowlett, JK; Rüedi-Bettschen, D; Spealman, RD, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoid X nuclear receptor alphaHomo sapiens (human)Potency9.71250.000817.505159.3239AID1159527; AID1159531
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)Ki0.02200.00000.419710.0000AID151001
Delta-type opioid receptorHomo sapiens (human)Ki1.00000.00000.59789.9300AID148369
Kappa-type opioid receptorHomo sapiens (human)Ki0.00030.00000.362410.0000AID148149
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1346329Human kappa receptor (Opioid receptors)2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID1346329Human kappa receptor (Opioid receptors)1990British journal of pharmacology, Sep, Volume: 101, Issue:1
CI-977, a novel and selective agonist for the kappa-opioid receptor.
AID1346329Human kappa receptor (Opioid receptors)1996Molecular pharmacology, Oct, Volume: 50, Issue:4
Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.
AID148729Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for I294K point mutations.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID151001Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID233830Selective inhibitory activity was determined against kappa & delta opioid receptor in chinese Hamster Ovary (CHO) cell membranes2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID148731Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for T109A point mutations.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID148725Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for E297A point mutations.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID148726Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for G319V point mutations.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID148149Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID148732Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for Y119A point mutations.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID148723Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for D138A point mutations.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID148730Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for S123A point mutations.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID233831Selective inhibitory activity was determined against kappa & mu opioid receptor in chinese Hamster Ovary (CHO) cell membranes2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID148369Inhibitory activity against Opioid receptor delta 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]naltrindole radioligand2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID246844In vivo opioid receptor activity in mouse hot plate assay2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.
AID148720Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for A298H point mutations.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID148728Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for I294A point mutations.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID148721Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for D105N point mutations.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID148727Compound was tested for the change in the Opioid receptor kappa 1 binding affinity (Ki(mut)/Ki(wild) for H291A point mutations.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists.
AID246888In vivo opioid receptor activity in mouse p-phenylquinone writhing assay2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.
AID246847In vivo opioid receptor activity in mouse tail flick assay2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.
AID1346329Human kappa receptor (Opioid receptors)2001European journal of pharmacology, Mar-02, Volume: 414, Issue:2-3
Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (82)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's62 (75.61)18.2507
2000's18 (21.95)29.6817
2010's2 (2.44)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.20 (24.57)
Research Supply Index4.49 (2.92)
Research Growth Index4.05 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (6.02%)5.53%
Reviews1 (1.20%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other77 (92.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]